Last reviewed 2026-05-14 · How we verify
Home › Drugs › Eli Lilly and Company › teriparatide 20 micrograms/day subcutaneous teriparatide 20 micrograms/day subcutaneous
At a glance
Generic name teriparatide 20 micrograms/day subcutaneous Also known as LY333334 Sponsor Eli Lilly and Company Modality Small molecule Phase Phase 3
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
Drug Landscape https://druglandscape.com/drug/teriparatide-20-micrograms-day-subcutaneous · Machine-readable: markdown · JSON · Editorial policy: /editorial-policy
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.